Urinary tract infection and pyelonephritis are clinical problems that frequently occur in children. Several factors are responsible for renal tissue injury, morbidity, and renal scarring after pyelonephritis. The aim of this study was to evaluate the preventive effect of L-carnitine on renal scarring in acute pyelonephritis.
A randomized double-blind clinical trial was conducted on 65 children aged 6 months to 10 years. Patients were randomized into 2 groups to receive 7-day treatment with only antibiotics without L-carnitine (control group; n = 32) and 7-day treatment with L-carnitine (case group; n = 33) during the acute phase of infection. Technetium-99m-labeled dimercaptosuccinic acid (DMSA) scintigraphy was performed for all children during the acute phase (in 2–7 days of hospitalization) and late phase. P-value less than 0.05 was statistically significant.
We recruited 65 participants in the study: 32 children in control group and 33 children in case group. Three children in the control group and 2 children in the case group refused to perform the second DMSA scan. Overall, data analysis at the end of the study was done on 60 patients. Age distribution of girl patients with upper urinary infection was 6.5% in girl children aged between 6 months and 12 months, 41.1% aged between 1 and 5 years, 33.3% aged between 5 and 10 years, respectively. There was no significant difference between 2 groups in age and sex. There was no significant difference between 2 groups in systolic blood pressure, diastolic blood pressure, the lab data including urine white blood cells and serum erythrocyte sedimentation rate, and antibiogram profiles. Voiding dysfunction was detected in 10% of the participants. The baseline DMSA was not significantly difference in 2 groups, but worsening of kidney lesions was significantly higher in control group after 6 months (P = 0.012).
Our study showed that L-carnitine significantly decreased renal scarring because of acute pyelonephritis.
1Department of Pediatric Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran;
2Department of Clinical Pharmacy, Faculty of Pharmacy-International Campus, Iran University of Medical Sciences, Tehran, Iran;
3Department of Physics and Medical Engineering, Isfahan University of Medical Sciences, Isfahan, Iran;
4Center for Health related social and behavioral sciences research, shahroud university of medical sciences, sharoud, Iran;
5Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; and
6Department of Physiology, Applied Physiology Research, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Address for correspondence: Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Hezar-Jerib Avenue, Isfahan 81746 73461, IR Iran. E-mail: firstname.lastname@example.org
The authors have no conflicts of interest to declare.
All authors conceptualized and designed the article. Also, all authors reviewed the whole paper and approved the final manuscript as submitted.